Nuclear Medicine Department, Centre Hospitalier Princesse Grace, 1 Avenue Pasteur, 98000, Monaco, Monaco.
Check-up Unit, Centre Hospitalier Princesse Grace, Monaco, Monaco.
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):260-268. doi: 10.1007/s00259-020-04968-8. Epub 2020 Jul 25.
[18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19.
Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients' profiles were classified as "inflammatory" or "low inflammatory." FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism.
Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome.
Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs.
NCT04441489. Registered 22 June 2020 (retrospectively registered).
[18F]-2-氟-2-脱氧-D-葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）是一种用于检测炎症过程的敏感且定量的技术。葡萄糖摄取与激活的炎症细胞（如单核细胞、淋巴细胞和粒细胞）中所见的无氧糖酵解增加相关。本研究的目的是评估非危重症 COVID-19 患者入院时炎症期假定高峰期的炎症状态。
前瞻性纳入因 COVID-19 入院的患者。FDG PET/CT 于症状发作的第 6 至 14 天进行。根据 FDG PET/CT 结果，将患者的特征分为“炎症”或“低度炎症”。比较 FDG PET/CT 数据与胸部 CT 演变和短期临床结局。报告所有炎症部位以筛查潜在的肺外嗜性。
共纳入 13 例患者。肺部的最大标准化摄取值范围为 4.7 至 16.3。所有患者均表现出纵隔淋巴结葡萄糖摄取增加。3 例（23%）患者出现轻度鼻咽部摄取增加，2 例（15%）患者出现骨髓摄取增加，5 例（38%）患者出现轻度脾脏葡萄糖摄取增加。无患者出现明显的消化道局灶性或节段性葡萄糖摄取。除 1 例外，所有患者的心肌均无明显生理性葡萄糖摄取。PET 肺部炎症状态与胸部 CT 演变或短期临床结局无相关性。
在 COVID-19 患者炎症期假定高峰期的 FDG PET/CT 扫描中，炎症过程明显。葡萄糖摄取呈异质性，通常集中在肺部。
NCT04441489。于 2020 年 6 月 22 日注册（回顾性注册）。
